RenalytixAI Reaches Milestone of KidneyIntelX Commercial Testing with Mount Sinai Health System
September 18, 2020
Salt Lake City-based RenalytixAI, today announced the commercial launch of the KidneyIntelX clinical test reporting platform within the Mount Sinai Health System. This means that KidneyIntelX risk assessment of progressive decline in kidney function or kidney failure, including education support for treating clinicians, is now commercially available for patients with early stage diabetic kidney disease (DKD).
“This development underscores the leadership of RenalytixAI in addressing chronic kidney disease, from diagnosis to drug discovery,” said Kelvyn Cullimore, president and CEO of BioUtah.
RenalytixAI plans to continue to add to the quality and capability of the KidneyIntelX platform, designed to provide potentially critical new information about the rate of disease progression and risk of kidney failure in early stage kidney disease. Last month, the company announced a study with Mt. Sinai to monitor and predict kidney risk in COVID-19 patients.
Recent News
- RefloDx Closes $2 Million Seed Round to Advance Noninvasive Testing for Chronic Throat and Voice Symptoms
- Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers
- Ultragenyx sells second rare pediatric PRV in a week for $203M
- Co-Diagnostics’ Joint Venture CoMira Diagnostics Invited by Saudi Ministry to Participate in Strategic Manufacturing Forum
- Route 92 Medical Announces $100 Million Corporate Debt Facility
- Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp
